CoChat
Cited by 216

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The complement system as a potential therapeutic target in rheumatic disease

Trouw, Leendert A., Pickering, Matthew C., Blom, Anna M. · 2017 · Nature Reviews Rheumatology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrrheum.2017.125

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 130

  1. Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: a defence system turning offensive. Nat. Rev. Nephrol. 12, 383–401 (2016). · DOI · Paper page
  2. Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14, 857–877 (2015). · DOI · Paper page
  3. Grumach, A. S. & Kirschfink, M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 61, 110–117 (2014). · DOI · Paper page
  4. Ram, S., Lewis, L. A. & Rice, P. A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23, 740–780 (2010). · DOI · Paper page
  5. Baines, A. C. & Brodsky, R. A. Complementopathies. Blood Rev. 31, 213–223 (2017). · DOI
  6. Nester, C. M. et al. Atypical aHUS: state of the art. Mol. Immunol. 67, 31–42 (2015). · DOI · Paper page
  7. Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N. Engl. J. Med. 368, 2169–2181 (2013). · DOI · Paper page
  8. Hillmen, P. et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 85, 553–559 (2010). · DOI · Paper page
  9. Hill, A., DeZern, A. E., Kinoshita, T. & Brodsky, R. A. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers 3, 17028 (2017). · DOI · Paper page
  10. Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233–1243 (2006). · DOI · Paper page
  11. Volokhina, E. J., et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.. Clin. Immunol. 160, 237–243 (2015). · DOI
  12. Sturfelt, G. & Truedsson, L. Complement in the immunopathogenesis of rheumatic disease. Nat. Rev. Rheumatol. 8, 458–468 (2012). · DOI
  13. McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328–2337 (2017). · DOI · Paper page
  14. Walport, M. J., Davies, K. A., Morley, B. J. & Botto, M. Complement deficiency and autoimmunity. Ann. NY Acad. Sci. 815, 267–281 (1997). · DOI
  15. Kotimaa, J. et al. Sex matters: systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components. Mol. Immunol. 76, 13–21 (2016). · DOI
  16. Okroj, M., Heinegard, D., Holmdahl, R. & Blom, A. M. Rheumatoid arthritis and the complement system. Ann. Med. 39, 517–530 (2007). · DOI · Paper page
  17. Holers, V. M. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology 221, 726–732 (2016). · DOI
  18. Brodeur, J. P., Ruddy, S., Schwartz, L. B. & Moxley, G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1531–1537 (1991). · DOI
  19. Corvetta, A. et al. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin. Exp. Rheumatol. 10, 433–438 (1992).
  20. Hogasen, K. et al. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J. Rheumatol. 22, 24–28 (1995).
  21. Jose, P. J., Moss, I. K., Maini, R. N. & Williams, T. J. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49, 747–752 (1990). · DOI
  22. Morgan, B. P., Daniels, R. H. & Williams, B. D. Measurement of terminal complement complexes in rheumatoid arthritis. Clin. Exp. Immunol. 73, 473–478 (1988).
  23. Moxley, G. & Ruddy, S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 28, 1089–1095 (1985). · DOI
  24. Swaak, A. J. et al. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases. Clin. Rheumatol. 6, 350–357 (1987). · doi:10.1007/bf02206833
  25. Kaplan, R. A. et al. Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor. Arthritis Rheum. 23, 911–920 (1980). · doi:10.1002/art.1780230806
  26. Kemp, P. A. et al. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37, 147–162 (1992).
  27. Trouw, L. A., Rispens, T. & Toes, R. E. Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 331–339 (2017). · DOI · Paper page
  28. Suwannalai, P. et al. Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann. Rheum. Dis. 73, 270–276 (2014). · DOI
  29. Trouw, L. A. et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 60, 1923–1931 (2009). · DOI · Paper page
  30. Happonen, K. E. et al. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 62, 3574–3583 (2010). · DOI
  31. Melin Furst, C. et al. The C-type lectin of the aggrecan G3 domain activates complement. PLoS ONE 8, e61407 (2013). · DOI
  32. Melin Furst, C. et al. Quantitative mass spectrometry to study inflammatory cartilage degradation and resulting interactions with the complement system. J. Immunol. 197, 3415–3424 (2016). · DOI
  33. Sjoberg, A., Onnerfjord, P., Morgelin, M., Heinegard, D. & Blom, A. M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 280, 32301–32308 (2005). · DOI · Paper page
  34. Sjoberg, A. P. et al. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol. Immunol. 46, 830–839 (2009). · DOI
  35. Trouw, L. A., Blom, A. M. & Gasque, P. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 45, 1199–1207 (2008). · DOI · Paper page
  36. Van Schravendijk, M. R. & Dwek, R. A. Interaction of C1q with DNA. Mol. Immunol. 19, 1179–1187 (1982). · doi:10.1016/0161-5890(82)90328-5
  37. Jiang, H. X., Siegel, J. N. & Gewurz, H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J. Immunol. 146, 2324–2330 (1991). · DOI
  38. Banda, N. K. et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183, 5928–5937 (2009). · DOI
  39. Mehta, G., Scheinman, R. I., Holers, V. M. & Banda, N. K. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 siRNA. J. Immunol. 194, 5446–5454 (2015). · doi:10.4049/jimmunol.1403012
  40. Wang, Y., Rollins, S. A., Madri, J. A. & Matis, L. A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl Acad. Sci. USA 92, 8955–8959 (1995). · DOI · Paper page
  41. Banda, N. K. et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177, 1904–1912 (2006). · DOI
  42. Banda, N. K., Takahashi, K., Wood, A. K., Holers, V. M. & Arend, W. P. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179, 4101–4109 (2007). · DOI
  43. Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157–168 (2002). · DOI · Paper page
  44. Banda, N. K. et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J. Immunol. 188, 1469–1478 (2012). · DOI
  45. Banda, N. K. et al. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J. Immunol. 193, 2455–2468 (2014). · doi:10.4049/jimmunol.1400752
  46. Katschke, K. J. Jr et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J. Exp. Med. 204, 1319–1325 (2007). · DOI
  47. Macor, P. et al. Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis Rheum. 64, 2559–2567 (2012). · DOI
  48. Durigutto, P. et al. Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS ONE 8, e58696 (2013). · DOI
  49. Blom, A. M., Nandakumar, K. S. & Holmdahl, R. C4b-binding protein (C4BP) inhibits development of experimental arthritis in mice. Ann. Rheum. Dis. 68, 136–142 (2009). · DOI
  50. Macedo, A. C. & Isaac, L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front. Immunol. 7, 55 (2016). · DOI · Paper page
  51. Taylor, P. R. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192, 359–366 (2000). · DOI · Paper page
  52. Nauta, A. J. et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 32, 1726–1736 (2002). · doi:10.1002/1521-4141(200206)32:6<1726::aid-immu1726>3.0.co;2-r
  53. Crow, M. K. & Kirou, K. A. Interferon-alpha in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16, 541–547 (2004). · DOI
  54. Lood, C. et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 60, 3081–3090 (2009). · DOI · Paper page
  55. Son, M., Santiago-Schwarz, F., Al-Abed, Y. & Diamond, B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc. Natl Acad. Sci. USA 109, E3160–E3167 (2012). · DOI · Paper page
  56. Gomes, R. C. et al. Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis: a Brazilian multicenter study. Arthritis Care Res. (Hoboken) 68, 1736–1741 (2016). · DOI
  57. Lintner, K. E. et al. Early components of the complement classical activation pathway in human systemic autoimmune diseases. Front. Immunol. 7, 36 (2016). · DOI · Paper page
  58. Leffler, J., Bengtsson, A. A. & Blom, A. M. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis. 73, 1601–1606 (2014). · DOI · Paper page
  59. Dragon-Durey, M. A., Blanc, C., Marinozzi, M. C., van Schaarenburg, R. A. & Trouw, L. A. Autoantibodies against complement components and functional consequences. Mol. Immunol. 56, 213–221 (2013). · DOI
  60. Trendelenburg, M., Marfurt, J., Gerber, I., Tyndall, A. & Schifferli, J. A. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum. 42, 187–188 (1999). · DOI
  61. Trouw, L. A. et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 114, 679–688 (2004). · DOI · Paper page
  62. Bao, L., Cunningham, P. N. & Quigg, R. J. Complement in lupus nephritis: new perspectives. Kidney Dis. (Basel) 1, 91–99 (2015). · DOI
  63. Sekine, H. et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J. Immunol. 166, 6444–6451 (2001). · DOI
  64. Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1–11 (2013). · DOI · Paper page
  65. Cornec, D., Cornec-Le Gall, E., Fervenza, F. C. & Specks, U. ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients. Nat. Rev. Rheumatol. 12, 570–579 (2016). · DOI · Paper page
  66. Falk, R. J., Terrell, R. S., Charles, L. A. & Jennette, J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl Acad. Sci. USA 87, 4115–4119 (1990). · DOI · Paper page
  67. Chen, M., Kallenberg, C. G. & Zhao, M. H. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat. Rev. Nephrol. 5, 313–318 (2009). · DOI
  68. Xiao, H., Schreiber, A., Heeringa, P., Falk, R. J. & Jennette, J. C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170, 52–64 (2007). · DOI · Paper page
  69. Schreiber, A. et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20, 289–298 (2009). · DOI · Paper page
  70. Chen, M., Jayne, D. R. W. & Zhao, M. H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 13, 359–367 (2017). · DOI · Paper page
  71. Xing, G. Q. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 29, 282–291 (2009). · doi:10.1007/s10875-008-9268-2
  72. Sethi, S. et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol. Dial. Transplant. 32, i139–i145 (2017). · DOI
  73. Yuan, J. et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res. Ther. 14, R140 (2012). · DOI
  74. Gou, S. J., Yuan, J., Chen, M., Yu, F. & Zhao, M. H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 83, 129–137 (2013). · DOI
  75. Camous, L. et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117, 1340–1349 (2011). · DOI · Paper page
  76. Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522–3531 (2012). · DOI · Paper page
  77. Wang, H., Wang, C., Zhao, M. H. & Chen, M. Neutrophil extracellular traps can activate alternative complement pathways. Clin. Exp. Immunol. 181, 518–527 (2015). · DOI · Paper page
  78. Bekker, P. et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS ONE 11, e0164646 (2016). · DOI
  79. Robinson, W. H. et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 580–592 (2016). · DOI · Paper page
  80. Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674–1679 (2011). · DOI · Paper page
  81. Struglics, A. et al. The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. Arthritis Res. Ther. 18, 223 (2016). · DOI
  82. Morgan, B. P., Boyd, C. & Bubeck, D. Molecular cell biology of complement membrane attack. Semin. Cell Dev. Biol. http://dx.doi.org/10.1016/j.semcdb.2017.06.009 (2017). · doi:10.1016/j.semcdb.2017.06.009
  83. Bradley, K. et al. Synthesis of classical pathway complement components by chondrocytes. Immunology 88, 648–656 (1996).
  84. Ritter, S. Y. et al. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum. 65, 981–992 (2013). · DOI · Paper page
  85. Lepus, C. M. et al. Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis. Arthritis Rheumatol. 66, 101–106 (2014). · DOI
  86. Bloom, A. C. et al. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, 253–261 (2016). · DOI
  87. Chimenti, M. S., Ballanti, E., Triggianese, P. & Perricone, R. Vasculitides and the complement system: a comprehensive review. Clin. Rev. Allergy Immunol. 49, 333–346 (2015). · DOI
  88. Jachiet, M. et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 67, 527–534 (2015). · doi:10.1002/art.38956
  89. Mahler, M., van Schaarenburg, R. A. & Trouw, L. A. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front. Immunol. 4, 117 (2013). · DOI
  90. Wisnieski, J. J. & Jones, S. M. IgG autoantibody to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. J. Rheumatol. 19, 884–888 (1992).
  91. Strait, R. T. et al. IgG1 protects against renal disease in a mouse model of cryoglobulinaemia. Nature 517, 501–504 (2015). · DOI
  92. Trendelenburg, M. et al. The role of complement in cryoglobulin-induced immune complex glomerulonephritis. J. Immunol. 175, 6909–6914 (2005). · DOI
  93. Hirt-Minkowski, P. et al. A trial of complement inhibition in a patient with cryoglobulin-induced glomerulonephritis. Case. Rep. Nephrol. Urol. 2, 38–45 (2012). · doi:10.1159/000339403
  94. Cicardi, M., Suffritti, C., Perego, F. & Caccia, S. Novelties in the diagnosis and treatment of angioedema. J. Investig. Allergol. Clin. Immunol. 26, 212–221 (2016). · DOI
  95. Montgomery, R. A. et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am. J. Transplant. 16, 3468–3478 (2016). · DOI · Paper page
  96. Pham, H., Santucci, S., Yang, W. H. Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure. Allergy Asthma Clin. Immunol. http://dx.doi.org/10.1186/s13223-014-0062-9 (2014). · doi:10.1186/s13223-014-0062-9
  97. Emmens, R. W. et al. On the value of therapeutic interventions targeting the complement system in acute myocardial infarction. Transl Res. 182, 103–122 (2017). · DOI
  98. Caliezi, C. et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52, 91–112 (2000). · DOI · Paper page
  99. Wong, E. K. & Kavanagh, D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 165, 306–320 (2015). · DOI
  100. Benamu, E. & Montoya, J. G. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr. Opin. Infect. Dis. 29, 319–329 (2016). · DOI
  101. Swaak, A. J. et al. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes. Rheumatol. Int. 2, 161–166 (1982). · doi:10.1007/bf00286138
  102. Pascual, M. et al. Metabolism of complement factor D in renal failure. Kidney Int. 34, 529–536 (1988). · DOI
  103. Ricklin, D. & Lambris, J. D. New milestones ahead in complement-targeted therapy. Semin. Immunol. 28, 208–222 (2016). · DOI
  104. Holers, V. M. et al. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin. Immunol. 28, 260–267 (2016). · DOI
  105. Fridkis-Hareli, M. et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118, 4705–4713 (2011). · DOI
  106. Atkinson, C. et al. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation 131, 1171–1180 (2015). · doi:10.1161/circulationaha.114.010482
  107. Grant, E. P. et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J. Exp. Med. 196, 1461–1471 (2002). · DOI · Paper page
  108. Vergunst, C. E. et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 46, 1773–1778 (2007). · DOI · Paper page
  109. Steinsson, K., Erlendsson, K. & Valdimarsson, H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum. 32, 906–913 (1989). · DOI
  110. Mehta, P. et al. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology (Oxford) 49, 823–824 (2010). · doi:10.1093/rheumatology/kep387
  111. Arkwright, P. D., Riley, P., Hughes, S. M., Alachkar, H. & Wynn, R. F. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J. Allergy Clin. Immunol. 133, 265–267 (2014). · DOI
  112. Olsson, R. F. et al. Allogeneic hematopoietic stem cell transplantation in the treatment of human C1q deficiency: the Karolinska experience. Transplantation 100, 1356–1362 (2016). · doi:10.1097/tp.0000000000000975
  113. Castellano, G. et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood. 103, 3813–3820 (2004). · DOI · Paper page
  114. Schwaeble, W. et al. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J. Immunol. 155, 4971–4978 (1995). · DOI
  115. van Schaarenburg, R. A. et al. The production and secretion of complement component C1q by human mast cells. Mol. Immunol. 78, 164–170 (2016). · DOI
  116. Bermea, R. S., Sharma, N., Cohen, K. & Liarski, V. M. Use of eculizumab in atypical hemolytic uremic syndrome, complicating systemic lupus erythematosus. J. Clin. Rheumatol. 22, 320–323 (2016). · doi:10.1097/rhu.0000000000000423
  117. El-Husseini, A. et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am. J. Kidney Dis. 65, 127–130 (2015). · doi:10.1053/j.ajkd.2014.07.031
  118. Raufi, A. G. et al. Atypical hemolytic uremic syndrome secondary to lupus nephritis, responsive to eculizumab. Hematol. Rep. 8, 6625 (2016). · DOI
  119. Pickering, M. C. et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54, 2286–2288 (2015).
  120. Coppo, R. et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr. Nephrol. 30, 167–172 (2015). · doi:10.1007/s00467-014-2944-y
  121. Strakhan, M. et al. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case. Rep. Hematol. 2014, 704371 (2014).
  122. Jayne, D. R. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2016111179 (2017). · DOI · Paper page
  123. Rosenblad, T. et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr. Nephrol. 29, 2225–2228 (2014). · DOI
  124. Prohaszka, Z., Nilsson, B., Frazer-Abel, A. & Kirschfink, M. Complement analysis 2016: clinical indications, laboratory diagnostics and quality control. Immunobiology 221, 1247–1258 (2016). · DOI
  125. Beurskens, F. J., van Schaarenburg, R. A. & Trouw, L. A. C1q, antibodies and anti-C1q autoantibodies. Mol. Immunol. 68, 6–13 (2015). · DOI
  126. Seelen, M. A. et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 296, 187–198 (2005). · DOI · Paper page
  127. Nilsson, B. & Ekdahl, K. N. Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol. 2012, 962702 (2012). · DOI
  128. Blom, A. M., Osterborg, A., Mollnes, T. E. & Okroj, M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol. Immunol. 66, 164–170 (2015). · DOI
  129. Noris, M., Mescia, F. & Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622–633 (2012). · DOI · Paper page
  130. Sciascia, S. et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol. Int. http://dx.doi.org/10.1007/s00296-017-3686-5 (2017). · DOI

Cited by

See all 216

Metadata

Authors
Trouw, L. A., Pickering, M. C., & Blom, A. M.
Venue
Nature Reviews Rheumatology
Published
2017-08-10
Volume
13
Issue
9
Pages
538-547
ISSN
  • 1759-4790 (ISSN-L)
  • 1759-4804
OpenAlex
W2742950097
Cited by
216
References
2
FWCI
1.60
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.